Article
Amodiaquine, its desethylated metabolite, or both, inhibit the metabolism of debrisoquine (CYP2D6) and losartan (CYP2C9) in vivo.
European journal of clinical pharmacology - 1 Jul 2006
Wennerholm Agneta, Nordmark Anna, Pihlsgård Maria, Mahindi Margarita, Bertilsson Leif, Gustafsson Lars L
Abstract excerpt
OBJECTIVE: To study the extent of in vivo inhibition by the antimalarial drug amodiaquine, its active metabolite N-desethylamodiaquine, or both, of the metabolism of four probe drugs of the enzymes CYP2D6, CYP2C19, CYP2C9 and CYP1A2. METHODS: Twelve healthy Swedish volunteers received a cocktail of four probe drugs (debrisoquine, omeprazole, losartan and caffeine) to determine their baseline metabolic capacities....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.